USPTO Art Unit 1645 Prosecution Statistics

Art Unit Information

Art Unit: 1645
Group: 1640
Tech Center: 1600
Total Cases: 15,635
Last Active: May 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19227585PHARMACEUTICAL COMPOSITION COMPRISING SUTTERELLA WADSWORTHENSIS AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF COLON CANCERJune 2025January 2026Allow710NoNo
19222494ENZYME-DECORATED NANOCATALYSTSMay 2025February 2026Allow911NoNo
19221315MITIGATION OF CRYPTOSPORIDIOSIS USING HYDROGEN PEROXIDE-GENERATING COMPOSITIONSMay 2025December 2025Allow710NoNo
19030138ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTAJanuary 2025July 2025Allow610NoNo
19030161ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTAJanuary 2025July 2025Allow610NoNo
19013448MUTANT PORESJanuary 2025March 2026Allow1410NoNo
18871201USE OF AKKERMANSIA MUCINIPHILA IN PREPARATION OF PHARMACEUTICAL COMPOSITION OR HEALTH CARE PRODUCT COMPOSITION FOR IMPROVING METABOLIC SYNDROMEDecember 2024July 2025Allow710NoNo
18944516BACILLUS STRAINS FOR IMPROVING FEED CONVERSION RATES AND BODY WEIGHT GAIN IN ANIMALSNovember 2024June 2025Allow710NoNo
18938752LACTIPLANTIBACILLUS PLANTARUM GOLDGUT-LP618 HAVING FUNCTION OF RESISTING SALMONELLA INFECTION AND APPLICATION THEREOFNovember 2024August 2025Allow920NoNo
18851087Hybridoma cell line secreting an ActA monoclonal antibody and use thereofSeptember 2024July 2025Allow1011NoNo
18895456LACTIPLANTIBACILLUS PLANTARUM EFFECTIVELY INHIBITING MULTI-DRUG-RESISTANT KLEBSIELLA PNEUMONIAE AND USE THEREOFSeptember 2024January 2025Allow410NoNo
18825396MICROBIAL COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASESSeptember 2024February 2025Allow510YesNo
18821883ENTERIC AEROBIZATION THERAPYAugust 2024February 2025Allow510NoNo
18814445MULTI-ANTIGEN DIAGNOSTIC FOR DETECTING LYME DISEASEAugust 2024January 2026Allow1731YesNo
18809763STRAIN OF LACTOBACILLUS HELVETICUS CAPABLE OF REMOVING MULTIPLE HEAVY METALS AND APPLICATION THEREOF IN GOAT MILK POWDERAugust 2024March 2025Allow711YesNo
18799714RELAXIN-2 FUSION PROTEINSAugust 2024February 2025Allow601NoNo
18787340LIVE TESTS FOR DIAGNOSIS OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY IN ANIMALS AND HUMANSJuly 2024April 2025Allow811YesNo
18777684CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPYJuly 2024February 2026Abandon1911NoNo
18768704VHH BASED BINDING ANTIBODIES FOR ANTHRAX AND BOTULINUM TOXINS AND METHODS OF MAKING AND USING THEREFORJuly 2024December 2025Abandon1701NoNo
18768336DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALSJuly 2024February 2025Allow700YesNo
18768920BACILLUS VELEZENSIS COMPOSITIONS AND METHODS OF USE THEREOFJuly 2024February 2025Allow710YesNo
18763332MITIGATION OF CRYPTOSPORIDIOSIS USING HYDROGEN PEROXIDE-GENERATING COMPOSITIONSJuly 2024March 2025Allow800NoNo
18761743RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USESJuly 2024November 2025Allow1620NoNo
18761709GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE VACCINE AND METHODS OF USEJuly 2024August 2025Abandon1410NoNo
18754918IMMUNOREACTIVE PEPTIDESJune 2024October 2024Allow301NoNo
18743295BISPECIFIC ANTIBODIES AND USES THEREOFJune 2024December 2025Abandon1811NoNo
18744293METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIESJune 2024December 2024Allow610YesNo
18742842Glyconjugate VaccinesJune 2024July 2025Allow1301YesNo
18741232PURIFIED CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAEJune 2024June 2025Allow1210NoNo
18738464Probiotic Method and Composition for Maintaining a Healthy Vaginal MicrobiomeJune 2024January 2025Allow810YesNo
18738385STRAIN OF SELENIUM-ENRICHED LACTIPLANTIBACILLUS PLANTARUM KD-2 AND APPLICATIONS IN PREPARING FERMENTED GOAT MILK AND GOAT MILK POWDERJune 2024April 2025Allow1011NoNo
18737799COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLSJune 2024April 2025Abandon1020YesNo
18734806OMPG VARIANTSJune 2024June 2025Allow1200YesNo
18734015MULTIVALENT PNEUMOCOCCAL VACCINESJune 2024March 2025Allow900NoNo
18680407NOVEL PEPTIDES AND THEIR USE IN DIAGNOSISMay 2024July 2025Allow1411NoNo
18676470COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLSMay 2024December 2024Allow720YesNo
18666594BACILLUS CALMETTE-GUERIN (BCG) AND ANTIGEN PRESENTING CELLS FOR TREATMENT OF BLADDER CANCERMay 2024September 2024Allow410NoNo
18665018MULTIVALENT OSPA POLYPEPTIDES AND METHODS AND USES RELATING THERETOMay 2024February 2025Allow900NoNo
18664120Cellular Adjuvants for Viral InfectionMay 2024February 2025Allow910NoNo
18664198Cellular Adjuvants for Viral InfectionMay 2024March 2025Allow1010NoNo
18663247CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USEMay 2024May 2025Allow1211NoNo
18662515MICROBIOME RELATED IMMUNOTHERAPIESMay 2024March 2025Allow1010NoNo
18660419IMMUNOGENIC COMPOSITIONS AND USES THEREOFMay 2024June 2025Allow1310NoNo
18659215PH20 Polypeptide Variants, Formulations and Uses ThereofMay 2024November 2024Allow620NoNo
18655708FimH Mutant, Compositions Therewith And Use ThereofMay 2024June 2025Allow1301YesNo
18654255COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND A FUNGICIDEMay 2024September 2025Abandon1611NoNo
18654243COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND A FUNGICIDEMay 2024April 2025Allow1211YesNo
18704718SYSTEMS AND METHODS FOR INCREASED PRODUCTION OF RECOMBINANT BIOPOLYMERS VIA GENOME ENGINEERING AND DOWNREGULATION OF BASAL EXPRESSIONApril 2024March 2025Allow1021YesNo
18644663COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND AN INSECTICIDEApril 2024September 2025Abandon1711YesNo
18644678COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND AN INSECTICIDEApril 2024September 2025Abandon1611NoNo
18641696METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY SKIN DISEASE WITH RECOMBINANT MICROORGANISMSApril 2024November 2025Allow1811YesNo
18637589METHODS FOR PRODUCING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CARRIER PROTEIN CONJUGATESApril 2024May 2025Allow1320NoNo
18636759HAEMOPHILUS INFLUENZAE SACCHARIDE-CARRIER CONJUGATE COMPOSITIONS AND USES THEREOFApril 2024June 2025Allow1420NoNo
18633691LONG LASTING EFFECT OF NEW BOTULINUM TOXIN FORMULATIONSApril 2024April 2025Allow1210NoNo
18633805DIETARY SUPPLEMENT COMPOSITION FOR TREATING AND MANAGING ACNEApril 2024September 2024Allow510YesNo
18632343OSTRICH ANTIBODY FOR BACTERIAL INFECTIOUS DISEASESApril 2024October 2025Allow1920NoNo
18629715NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONSApril 2024January 2025Allow1001NoNo
18626126MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONSApril 2024August 2025Abandon1710NoNo
18624353ANTI-STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY AND NUCLEIC ACID ENCODING SEQUENCE THEREOF, AND USES OF THE SAMEApril 2024March 2025Allow1211NoNo
18620483Method and System to Modify an Individual’s Gut-Brain Axis to Provide Neurocognitive ProtectionMarch 2024February 2025Allow1010NoNo
18615672Modulation of an Individual's Gut Microbiome to Address Osteoporosis and Bone DiseaseMarch 2024March 2025Allow1120YesNo
18610886COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER USING BACTERIAMarch 2024November 2025Abandon2011NoNo
18611637MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION, AND METHODS AND USES THEREOFMarch 2024August 2025Allow1720NoNo
18609229Treatment of WartsMarch 2024May 2025Allow1410NoNo
18609596IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOFMarch 2024June 2025Abandon1510NoNo
18609152METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONSMarch 2024May 2025Allow1410NoNo
18606817ANTIGENIC TRIPEPTIDES DERIVED FROM MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS S-TYPE STRAINS, DERIVATIVES AND USES THEREOFMarch 2024June 2025Allow1511NoNo
18606135ANTIBODIES AND METHODS OF USEMarch 2024September 2025Abandon1801NoNo
18605436GLYCOSYLATED COMP PILIN VARIANTS, METHODS OF MAKING AND USES THEREOFMarch 2024November 2025Allow2011NoNo
18601211COMPLEX OF BOTULINUM NEUROTOXIN E AND ITS BINDING PROTEIN AS A FORMULATION WITH ENHANCED POTENCYMarch 2024March 2025Allow1210YesNo
18599359ANTIBODIES AGAINST MICROORGANISMS AND USES THEREOFMarch 2024June 2025Abandon1601NoNo
18600406PRODUCTION OF INDOLE-DERIVED METABOLITES BY SHELF-STABLE COMMUNITIES OF SAFE BACTERIAMarch 2024October 2025Abandon1930YesNo
18600195AGENT FOR INDUCING INTERFERON PRODUCTION CONTAINING LACTIC ACID BACTERIAMarch 2024August 2025Allow1711YesNo
18598439STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND IMMUNOGENIC CONJUGATE THEREOFMarch 2024April 2025Allow1310NoNo
18596916ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOFMarch 2024March 2025Allow1210NoNo
18594291COMPOSITIONS FOR USE IN TREATMENT OF CHLAMYDIAMarch 2024November 2024Allow820YesNo
18593739Enhanced Microbial Therapeutic AgentsMarch 2024February 2025Allow1112YesNo
18591306Prevotella Copri CompositionsFebruary 2024April 2025Allow1310NoNo
18590885AGROBACTERIUM FOR REDUCING UPTAKE OF HEAVY METALS BY WHEAT AND USE THEREOFFebruary 2024May 2025Abandon1411NoNo
18589539MICROBIAL COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASESFebruary 2024August 2024Allow510YesNo
18589804Monoclonal Antibody Against Canine Fibroblast Activation Protein that Cross-Reacts with Mouse and Human Fibroblast Activation Protein (FAP)February 2024February 2026Abandon2421NoNo
18584070METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASESFebruary 2024May 2025Allow1520NoNo
18581838USE OF AKKERMANSIA IN THE TREATMENT OF ORAL DISEASESFebruary 2024August 2025Allow1820YesNo
18443739RECOMBINANT VACCINE AGAINST HELMINTHS IN PICHIA PASTORIS AND METHODS FOR PRODUCING AND PURIFYING PROTEINS FOR USE AS VACCINES AGAINST HELMINTHSFebruary 2024December 2025Abandon2220YesNo
18442348METHODS OF IMPROVING DESIRABLE TRAITS IN FOWLFebruary 2024June 2025Abandon1601NoNo
18442506CATTLE FEVER TICK-INFESTATION VACCINES AND USES THEREOFFebruary 2024February 2025Allow1210NoNo
18442487OPTIMIZED EPICUTANEOUS VACCINATIONFebruary 2024February 2026Abandon2420NoNo
18441408PREPARATION OF LIVE VACCINESFebruary 2024April 2025Abandon1410YesNo
18440278MUTANT POREFebruary 2024March 2025Allow1301YesNo
18440212MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDESFebruary 2024May 2025Allow1510NoNo
18438693ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTIONFebruary 2024December 2025Allow2210NoNo
18437999ANTIBODY CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES FOR REGULATING CELLULAR THERAPIESFebruary 2024September 2025Abandon1901NoNo
18437816COMBINATION TREPONEMAL AND NON-TREPONEMAL SYPHILIS TESTFebruary 2024April 2025Allow1510NoNo
18435440FIBROBLAST GROWTH FACTOR-21-FC FUSION PROTEINSFebruary 2024September 2025Allow1911NoNo
18430254ETHYL 2-[9-(2-HYDROXYPYRIDIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024March 2025Allow1420NoNo
18430068IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINESFebruary 2024October 2025Abandon2110NoNo
18430166FIBROSIS MODEL AND METHODS OF USE THEREOFFebruary 2024August 2025Abandon1911NoNo
18428425ANTI-PARASITIC IMMUNOLOGICAL COMPOSITIONSJanuary 2024February 2026Allow2421NoNo
18425772MONOCLONAL ANTIBODY AND VACCINE TARGETING FILAMENTOUS BACTERIOPHAGEJanuary 2024February 2026Allow2512YesNo
18424354SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOFJanuary 2024May 2025Allow1511NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1645.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
149
Examiner Affirmed
93
(62.4%)
Examiner Reversed
56
(37.6%)
Reversal Percentile
72.4%
Higher than average

What This Means

With a 37.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1453
Allowed After Appeal Filing
337
(23.2%)
Not Allowed After Appeal Filing
1116
(76.8%)
Filing Benefit Percentile
11.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1645 - Prosecution Statistics Summary

Executive Summary

Art Unit 1645 is part of Group 1640 in Technology Center 1600. This art unit has examined 15,635 patent applications in our dataset, with an overall allowance rate of 63.9%. Applications typically reach final disposition in approximately 31 months.

Comparative Analysis

Art Unit 1645's allowance rate of 63.9% places it in the 20% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1645 receive an average of 1.98 office actions before reaching final disposition (in the 58% percentile). The median prosecution time is 31 months (in the 46% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.